Skip to content

The Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis

The Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00001375
Enrollment
500
Registered
2002-12-10
Start date
1994-08-31
Completion date
2000-06-30
Last updated
2008-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Arthritis, Reactive, Arthritis, Rheumatoid, Reiter's Disease, Synovitis

Keywords

Infection, Reactive Arthritis, Rheumatoid Arthritis, Synovial Biopsy, Synovial Fluid, Synovitis

Brief summary

This study will evaluate patients with inflammatory forms of arthritis within the first year of onset. The study will attempt to clarify factors that may predict disease course such as evolution into rheumatoid arthritis (RA) or other chronic inflammatory arthropathies. Synovial biopsies and synovial fluid will be obtained to search for microbial agents and other initiating and modulating factors that may be most readily distinguished early in the disease and to determine the stage of disease at which certain immunologic and hormonal changes become evident. The study will also search for genetic and other features that may be associated with specific forms of inflammatory arthropathies that might predict the subsequent clinical disease course or response to different agents used in treatment of RA, Reiter's syndrome and other types of chronic inflammatory arthropathies.

Detailed description

This study will evaluate patients with inflammatory forms of arthritis within the first year of onset. The study will attempt to clarify factors that may predict disease course such as evolution into rheumatoid arthritis (RA) or other chronic inflammatory arthropathies. Synovial biopsies and synovial fluid will be obtained to search for microbial agents and other initiating and modulating factors that may be most readily distinguished early in the disease and to determine the stage of disease at which certain immunologic and hormonal changes become evident. The study will also search for genetic and other features that may be associated with specific forms of inflammatory arthropathies that might predict the subsequent clinical disease course or response to different agents used in treatment of RA, Reiter's syndrome and other types of chronic inflammatory arthropathies.

Interventions

None listed

Sponsors

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Lead SponsorNIH

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

Patients to be studied will be required to have an inflammatory arthritis of less than one year's duration. Patients must be greater than 18 years of age. Pregnant patients may be entered into the study, but they will not undergo percutaneous needle biopsy or joint radiographs. No patients with known bacterial septic arthritis, crystal-induced, or degenerative arthritis. Synovial biopsies will not be performed if patients have platelet counts less than 70,000/mm(3), other bleeding diathesis in the skin over the joint or sepsis. Joint MRI: Patient must currently be evaluated at the NIH through protocol 94-AR-0194 or 98-AR-0150. Joint MRI: Patient must have at least one clinically active arthritic joint that is under consideration for percutaneous needle synovial biopsy. Joint MRI: Patients must not have the following: cardiac pacemakers, auto defibrillators, neural stimulators, aneurysm clips, metallic prostheses, cochlear (ear) implants, any implanted devices (pumps, infusion devices, etc.), metal fragments in the eye, or shrapnel injuries. Joint MRI: Patients must not exceed the size limitations of the MRI scanner. Joint MRI: Must not suffer from claustrophobia. Joint MRI: Must not have had a previous anaphylactoid reaction to gadolinium-based contrast material. Joint MRI: Must not be pregnant.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026